Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer

BACKGROUND AND OBJECTIVE: In the USA, cabozantinib was approved for the treatment of patients aged ≥ 12 years with radioiodine-refractory differentiated thyroid cancer (DTC) who progressed on prior vascular endothelial growth factor (VEGFR)-targeted therapy based on the Phase 3 COSMIC-311 trial, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ly, Neang S., Li, Jing, Faggioni, Raffaella, Roskos, Lorin K., Brose, Marcia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085936/
https://www.ncbi.nlm.nih.gov/pubmed/36869986
http://dx.doi.org/10.1007/s40262-023-01210-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085936/
https://www.ncbi.nlm.nih.gov/pubmed/36869986
http://dx.doi.org/10.1007/s40262-023-01210-0

Ejemplares similares